Posted 9th January 2019 by Jane Williams
Bas Trietsch is the CTO and co-founder of MIMETAS and co-inventor of the OrganoPlate. As CTO he currently drives the continued product development of the OrganoPlate and its peripheral equipment.
Here, Bas talks about what the future holds for organ-on-a-chip and other breakthroughs technologies in biology.
Posted 17th December 2018 by Jane Williams
As industry developments continue to improve, the potential for personalised medicine and the possibility of individual diagnosis is on the horizon. These slides, from the Precision Medicine & Biomarkers Leaders Summit: Europe are now available from Andres Hurtado-Lorenzo, Thorsten Gutjahr & Thomas Skot Jensen.
Neurobehavioural Screening, Microfabricated Platforms and Medical Device Innovation with Microfluidics
Posted 10th December 2018 by Jane Williams
Microfluidics is revolutionising the way patients are diagnosed, monitored and treated. If you weren’t able to attend the 4BIO Summit in San Francisco, we have made these presentation slides from Suvajyoti Guha, Dr Todd Thorsen & Pouya Rezai available here.
Posted 5th December 2018 by Jane Williams
2018 will be remembered as a decisive year for immuno-oncology. In particular, Nobel Prize winners James Allison of MD Anderson Cancer Center in Houston, Texas, and Tasuku Honjo of Kyoto University in Japan lifted the field of immunotherapy to international recognition for those outside the scientific and medical communities. For the patient, these new alternatives to standard oncology therapies offer new hope for life-extending treatments using immunotherapy.
Failing Blockbuster Medicines, Eroding Operator Margins & Increased Pricing Pressures: What’s Next for Precision Medicine?
Posted 12th September 2018 by Jane Williams
The Precision Medicine and Biomarkers Leaders Summit: Europe takes place this week and in anticipation, we spoke to Unmesh Lal of Frost and Sullivan about his views on what the future holds for precision medicine and how the pharmaceutical industry has changed in recent times.
Posted 10th January 2018 by Jane Williams
Pathology is dealing with an area of diagnostics that is extremely variable. General pathologists are able to diagnose virtually any disease, but in rare or complex cases it is common practice to consult an expert.
Posted 29th December 2017 by Jane Williams
Honey Reddi, Clinical Laboratory Director at the Jackson Laboratory spoke at the 4th Global Precision Medicine and Biomarkers Leader Summit. She gives us an insight on liquid biopsies in the clinic and the effectiveness of current treatment.
Posted 5th July 2017 by Jane Williams
Here, we use the term molecular diagnostics to refer to tests that detect the presence of specific nucleic acids in a clinical specimen such as blood, urine, faeces, saliva, and tissue. These nucleic acids serve, among other things, as biomarkers for the presence of infection-causing pathogens (e.g., DNA and/or RNA from bacteria, virus, and/or parasites); diseases such as cancer (characterised by mutant alleles), and genetic abnormalities.